Nestle Skin Health SA
www.nestleskinhealth.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nestle Skin Health SA
Galderma Readies Its First Therapeutic Biologic For Two US Launches In 2024
Galderma said its IL-31 receptor alpha inhibitor nemolizumab succeeded in two Phase III atopic dermatitis trials, advancing the firm’s long-term goal of moving past topical dermatology drugs.
Nestle, Bullish On Palforzia, To Buy Remainder Of Aimmune
Since Palforzia likely will be the only peanut allergy drug on market for some time, Nestle announces it will pay about $2.6bn to acquire the 80% of Aimmune it doesn’t own.
Cellular Biomedicine To Go Private In Consortium Buyout
Deal Snapshot: The China/US CAR-T firm will be bought out by its management team and institutional investors in a deal structured as a merger into a new company.
Company Information
- Industry
- Medical Devices
-
Pharmaceuticals
- OTC, Consumer
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice